Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response

Haematologica. 2003 Dec;88(12):1425-6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Benzamides
  • Clone Cells / chemistry
  • Clone Cells / ultrastructure
  • DNA Mutational Analysis
  • DNA, Neoplasm / genetics*
  • Drug Resistance, Neoplasm
  • Fusion Proteins, bcr-abl / genetics*
  • Genes, abl*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myeloid, Chronic-Phase / drug therapy
  • Leukemia, Myeloid, Chronic-Phase / genetics*
  • Mutation, Missense
  • Piperazines / therapeutic use*
  • Point Mutation*
  • Polymerase Chain Reaction
  • Protein Structure, Tertiary / genetics
  • Pyrimidines / therapeutic use*
  • Treatment Outcome

Substances

  • Benzamides
  • DNA, Neoplasm
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl